<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Galal, Mohammed Omar</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The High Cost of Untreated CHD</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">27-27</style></pages><abstract><style  face="normal" font="default" size="100%">Globally, pulmonary vascular disease associated with congenital heart disease (CHD) may be the most preventable cause of pulmonary artery hypertension and related mortality and morbidity [Adatia I et al. Chest 2010]. This article presents an overview of advanced and combination therapies in patients with pulmonary arterial hypertension-CHD.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>